| Catalog No. | HF869016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | GDF11, BMP-11, BMP11, Growth/differentiation factor 11, GDF-11, Bone morphogenetic protein 11 |
|---|
| Concentration | 7mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | O95390 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1457°C. |
|---|
| Alternate Names | ACE-536,luspatercept–aamt,CAS:1373715-00-4 |
|---|
| Background | Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
